EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

Sponsor: M.D. Anderson Cancer Center

Sponsor score: 0

ClinicalTrials ID:NCT06897488

This Phase II trial evaluates radiotherapy alone post-lumpectomy in patients aged ≥60 with early-stage, low-risk ER+ breast cancer. It aims to assess 3-year DMFS, HRQoL, recurrence rates, survival, and toxicities. Eligibility includes confirmed invasive cancer, T1/T2 stage, ER/PR positive, HER2- non-amplified, and negative surgical margins. Participants receive adjuvant radiotherapy.

Patient Parameters

Program Overview

This clinical research study is to learn about the effects of giving radiotherapy alone after lumpectomy to patients who have early-stage, low-risk breast cancers and who are 60 years of age or older.

Description

Primary Objective:

To determine the 3- year DMFS rate of radiotherapy as adjuvant monotherapy for early stage, low risk breast cancers in patients aged ≥ 60 years

Secondary Objectives:

  1. To determine the HRQoL of patients ≥ 60 years with early stage, low risk breast cancer receiving adjuvant monotherapy with radiotherapy
  2. To determine the 3-year and 5-year risk of ipsilateral breast tumor recurrence (IBTR) for early-stage breast cancers treated with lumpectomy and adjuvant radiotherapy without endocrine therapy
  3. To quantify the 3-year and 5-year rates of local-regional recurrence, contralateral breast cancer, breast cancer-specific survival and overall survival and the 5 year rate of DMFS
  4. To determine the 5-year utilization of salvage mastectomy and other salvage therapies
  5. To determine late (up to 11 year) oncologic outcome data for patients accessible via chart review or phone call
  6. To determine the toxicities experienced by patients ≥ 60 years with early stage, low risk breast cancer receiving adjuvant monotherapy with radiotherapy

Eligibility Criteria

Inclusion Criteria

  1. Diagnosis of pathologically-confirmed invasive breast cancer
  2. Age ≥ 60 years
  3. Treatment with breast conserving surgery
  4. Pathologic T stage of T1 or T2 with total tumor size ≤ 3cm including any component of DCIS that may exist in conjunction with invasive disease
  5. Ki-67 ≤ 20%
  6. Final surgical margins negative, defined as no tumor on ink. Lobular carcinoma in situ involving the final surgical margin will be disregarded.
  7. Tumor must be estrogen receptor positive, progesterone receptor positive and HER2Neu non-amplified as per current College of American Pathologists guidelines
  8. Clinical nodal stage cN0
  9. If pathologic nodal staging is obtained, then pN0 or pN0(i+)
  10. Patients have had or have a scheduled discussion with a breast medical oncologist regarding adjuvant treatment options

Exclusion Criteria

  1. Node positive disease (N1-3)
  2. Metastatic disease (M1)
  3. Grade 3 disease and lymphovascular space invasion in the tumor
  4. Synchronous bilateral breast cancer
  5. Receipt of neoadjuvant therapy
  6. Diagnosis of a collagen vascular disease associated with an increased incidence of radiation toxicities such as scleroderma or systemic lupus erythematosis
  7. Diagnosis of other cancer within the prior 5 years, excluding basal or squamous cell carcinoma of the skin that has been treated
  8. Patient with psychiatric illness/social situations that would limit compliance with study requirements
  9. Prior radiotherapy to the index breast or recurrent cancer of the breast
  10. Known carrier of a mutation associated with predisposition to breast cancer development, including BRCA1 or BRCA2

Locations

FACILITYZIPCITYSTATE
The University of Texas M. D. Anderson Cancer Center77030HoustonTexas

Get This Program In Your Inbox

You can sign up and apply your patients for this program.